• gmp-verlag.de
  • GMP MANUAL Login
  • Shopping cart
Stay informed!

You’d like to be regularly informed on the latest developments in Good Manufacturing Practices?


Subscribe to our free GMP Newsletter LOGFILE!


The New USP <1231>
Water for Pharmaceutical Purposes

a detailed Overview


Award for the
GMP Compliance Adviser

GMP knowledge that convinces.


On 7 June 2016 Maas & Peither GMP Publishing has received a

SIPAward in the category
"Best New Success Story" and was awarded with the 3rd place.

The GMP MANUAL (now: GMP Compliance Adviser) impressed the jury with "Safe Drugs through Better GMP Understanding".

GMP Compliance Adviser

GMP in Practice: 24 chapters written by internationally renowned industry experts.


GMP Regulations: 8 chapters with the most important GMP guidelines and regulations.




TOP 5 GMP Downloads

1. Questionnaire for preparing GMP-inspections
More than 650 typical questions related to audits and inspections.

2. GDP Audit Checklist
More than 700 questions with reference to regulations.

3. GMP Fundamentals
A quick and comprehensive overview of the complex world of GMP.

4. Industry Guide to handle OOX Test Results
Every single step of the OOX process.

5. The New USP <1231>: Water for Pharmaceutical Purposes
A compact overview of the contents of the new version of USP <1231>.

>>> More Downloads

News about GMP/cGMP


EMA Management Board: Highlights of the March 2018 Meeting

The European Medicines Agency (EMA) discussed the following points at its 15 March meeting in London:


  • Increasing availability of veterinary medicines for minor use and minor species
  • Review of clinical trial portal and database
  • Advanced therapies: achievements and challenges
    The term “Advanced Therapy Medicinal Products” (ATMPs) is used to designate gene therapies, somatic cell therapies and tissue engineered products.
    Achievements and continuing scientific and regulatory challenges relating to advanced therapies were presented by Dr. Martina Schüssler-Lenz, chair of EMA’s Committee for this field.
    Ten advanced therapies have been granted an EU-wide marketing authorisation since 2009. Four advanced therapies are currently under evaluation, including one cell-based and three gene-based therapies. For 2018, it is expected that four additional medicines will be getting evaluated.
  • Monitoring of EMA independence policies
  • Update on Brexit (as reported)

EMA: News and Events


No comment has yet been written about this news.
Literature recommendation
GMP Compliance Adviser
Single User Licence (monthly subscription)